Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMC

Vascular Regeneration in Peripheral Artery Disease

Cooke JP., Meng S.

Clinical Trial on Cardiovascular Disease, Peripheral Artery Disease, Stroke Research, published in Arterioscler Thromb Vasc Biol (2020) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Arterioscler Thromb Vasc Biol (2020)
Reported sample size
—
Source database
Europe PMC
PMID
32434408
PMCID
PMC7357605
DOI
10.1161/atvbaha.120.312862
Citations
94

Abstract (original English)

Peripheral artery disease is a common disorder and a major cause of morbidity and mortality worldwide. Therapy is directed at reducing the risk of major adverse cardiovascular events and at ameliorating symptoms. Medical therapy is effective at reducing the incidence of myocardial infarction and stroke to which these patients are prone but is inadequate in relieving limb-related symptoms, such as intermittent claudication, rest pain, and ischemic ulceration. Limb-related morbidity is best addressed with surgical and endovascular interventions that restore perfusion. Current medical therapies have only modest effects on limb blood flow. Accordingly, there is an opportunity to develop medical approaches to restore limb perfusion. Vascular regeneration to enhance limb blood flow includes methods to enhance angiogenesis, arteriogenesis, and vasculogenesis using angiogenic cytokines and cell therapies. We review the molecular mechanisms of these processes; briefly discuss what we have learned from the clinical trials of angiogenic and cell therapies; and conclude with an overview of a potential new approach based upon transdifferentiation to enhance vascular regeneration in peripheral artery disease.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
ArteriesAnimalsHumansCytokinesAngiogenesis Inducing AgentsTreatment OutcomeStem Cell TransplantationRecovery of FunctionRegenerationRegional Blood Flow

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research